融捷健康(300247) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥102,969,850.43, representing an increase of 8.94% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥4,648,112.77, a significant increase of 25.18% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,276,300.66, up 4.49% from the previous year[5]. - The basic earnings per share for Q3 2023 was ¥0.0058, an increase of 26.09% year-on-year[5]. - Total operating revenue for the current period reached ¥374,171,590.65, an increase of 13.14% compared to ¥330,663,140.51 in the previous period[32]. - Net profit for the current period was ¥38,691,932.62, a decrease of 73.5% from ¥146,229,493.28 in the previous period[34]. - Operating profit decreased to ¥49,683,497.68 from ¥154,732,798.88, representing a decline of 67.9%[34]. - The basic and diluted earnings per share were both ¥0.0319, a decrease from ¥0.1718 in the previous period[34]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥1,207,725,560.77, reflecting a growth of 1.76% compared to the end of the previous year[5]. - The company's total assets as of September 30, 2023, amount to CNY 1,207,725,560.77, an increase from CNY 1,186,803,628.67 at the beginning of the year[30]. - Current assets total CNY 803,937,267.25, up from CNY 766,734,840.18 at the start of the year[29]. - Total liabilities decreased to CNY 135,425,873.14 from CNY 158,030,326.94[30]. - The company's equity attributable to shareholders increased to CNY 1,017,267,489.63 from CNY 988,955,398.44[31]. - The company’s non-current assets total CNY 403,788,293.52, down from CNY 420,068,788.49[30]. Cash Flow - The cash flow from operating activities for the year-to-date period increased by 250.01% to ¥81,659,647.96[5]. - The net cash flow from operating activities increased by ¥136,096,000 compared to the same period last year, driven by higher sales revenue and collection of receivables[26]. - Cash flow from operating activities generated a net amount of ¥81,659,647.96, a significant recovery from a negative cash flow of -¥54,436,363.18 in the previous period[37]. - Cash and cash equivalents at the end of the period totaled ¥114,555,168.95, compared to ¥21,678,949.24 at the end of the previous period[37]. - The company's cash and cash equivalents increased to CNY 114,555,168.95 from CNY 68,300,201.59[29]. Receivables and Inventory - The company reported a decrease in accounts receivable by ¥11,605,500, a decline of 29.63%, primarily due to the collection of previous receivables[10]. - The company reported a decrease in accounts receivable from CNY 39,167,801.51 to CNY 27,562,254.44[29]. - The company experienced a decrease in inventory by ¥44,060,500, a drop of 23.62%, attributed to the sale of last year's stock[13]. Investment Income - The company reported a decrease in investment income of ¥130,824,500 compared to the previous year, primarily due to the absence of equity transfer gains in the current period[19]. - The company experienced a significant drop in investment income, reporting ¥1,874,302.68 compared to ¥132,698,822.50 in the previous period[32]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,360[27]. - The largest shareholder, Rongjie Investment Holdings, holds 14.54% of shares, totaling 116,912,302 shares[27]. - The company has no preferred shareholders as of the reporting period[28]. Research and Development - The company reported a decrease in research and development expenses to ¥6,547,019.26 from ¥7,904,373.99, a reduction of 17.2%[32]. Other Comprehensive Income - Other comprehensive income after tax for the current period was ¥4,834,453.28, down from ¥45,191,002.84 in the previous period[34]. Audit Status - The third quarter report of Rongjie Health Technology Co., Ltd. is unaudited[39].